Munich – Formycon AG has completed a capital increase against cash contributions from its approved capital, and under exclusion of subscription rights, in the amount of 435,920 shares. With the successful completion of this transaction, the company’s registered capital rises from EUR 8,626,683.00 to EUR 9,062,603.00, an increase of EUR 435,920.00. The newly issued shares have been privately placed to selected institutional investors and family offices, notably including a U.S. healthcare fund, at a price of EUR 25.50 per share. Proceeds from the share placement in the gross amount of EUR 11,115,960.00 will flow entirely to the company and are to be used to advance and expand the company’s biosimilar development programs in accordance with its plans, thus further strengthening the market position which Formycon has already achieved. With this capital transaction, the company’s total holdings in cash and marketable securities will rise to approx. EUR 21.3 million. The entry of a major U.S. fund into the Formycon investor base underscores the high level of interest among international investors in the rapidly developing market for biosimilar drugs, as well as the strategic importance to the company of the North American market. First Berlin Securities Brokerage GmbH served as advisor to Formycon for this transaction.
We will keep you up to date!News Distributor Subscription